Shi Hou
Shi Hou has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Junhai Xiao
State Key Laboratory of National Security Specially Needed Medicines
3 shared publicationsZe Ye
State Key Laboratory of National Security Specially Needed Medicines
3 shared publicationsBinrong Yao
State Key Laboratory of National Security Specially Needed Medicines
2 shared publications- Cheng Xing
Jilin University
2 shared publications Huining Cao
State Key Laboratory of National Security Specially Needed Medicines
2 shared publications- Jialin Guo
State Key Laboratory of National Security Specially Needed Medicines
2 shared publications
Latest Publications
- 8 October 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (20) , 21701-21724
Design, Synthesis, and Biological Evaluation of Indole Derivatives Targeting LsrK as AI-2 Quorum Sensing Inhibitors
A series of novel indole derivatives targeting LsrK as AI-2 quorum sensing (QS) inhibitors against antimicrobial resistance (AMR) were designed, synthesized, and evaluated in vitro and in vivo. 3-Cyano-indol derivative A19 showed more potent activity than that of all reported LsrK inhibitors, with an IC50 value of 340 nM and a KD value of 485 nM. The in-depth biological evaluation indicated that the potent compounds A19, A40, and A49 inhibited biofilm formation and bacterial motility and changed biofilm morphology through AI-2 QS inhibition rather than direct antibacterial effects. Surprisingly, they showed the synergistic eradication effect for preformed biofilms combined with antibiotics and no obvious in vitro hemolysis and cellular toxicity. Moreover, the best-performing compound A40 showed favorable oral PK properties. In summary, this work identified that A40 was a promising lead with a novel scaffold for the further development of LsrK inhibitors as AI-2 QS inhibitors against AMR.
- 8 October 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (20) , 21701-21724
Design, Synthesis, and Biological Evaluation of Indole Derivatives Targeting LsrK as AI-2 Quorum Sensing Inhibitors
A series of novel indole derivatives targeting LsrK as AI-2 quorum sensing (QS) inhibitors against antimicrobial resistance (AMR) were designed, synthesized, and evaluated in vitro and in vivo. 3-Cyano-indol derivative A19 showed more potent activity than that of all reported LsrK inhibitors, with an IC50 value of 340 nM and a KD value of 485 nM. The in-depth biological evaluation indicated that the potent compounds A19, A40, and A49 inhibited biofilm formation and bacterial motility and changed biofilm morphology through AI-2 QS inhibition rather than direct antibacterial effects. Surprisingly, they showed the synergistic eradication effect for preformed biofilms combined with antibiotics and no obvious in vitro hemolysis and cellular toxicity. Moreover, the best-performing compound A40 showed favorable oral PK properties. In summary, this work identified that A40 was a promising lead with a novel scaffold for the further development of LsrK inhibitors as AI-2 QS inhibitors against AMR.
- 29 April 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (9) , 9407-9430
Design, Synthesis, and Biological Evaluation of Selective STING Synergists That Enhance cGAMP-STING Pathway Activation without Inherent Agonist Activity
The cGAS-STING pathway is pivotal for innate immunity and antitumor responses. However, the challenge of selectively targeting the diseased tissue without harming the healthy tissue has impeded the development of STING agonists. In this article, we tackle this issue by developing novel STING synergists that target the STING C-terminal domain pocket. Our findings indicate that agonist 12B can boost the cGAMP-STING pathway synergistically. Through reverse optimization of 12B, we synthesized three series of compounds, with compounds 55, 66, and 67 emerging as selective STING synergists that amplify cGAMP-induced pathway activation without inherent agonist properties. Compound 67 emerged as the most potent (EC50 = 20.53 μM), displaying a broad binding affinity across STING-CTD alleles and potent antitumor efficacy in vivo. Notably, it exhibited excellent safety profiles in both in vitro and in vivo models, along with favorable pharmacokinetics. These findings highlight the therapeutic potential of novel STING synergists for cancer immunotherapy.
- 29 April 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (9) , 9407-9430
Design, Synthesis, and Biological Evaluation of Selective STING Synergists That Enhance cGAMP-STING Pathway Activation without Inherent Agonist Activity
The cGAS-STING pathway is pivotal for innate immunity and antitumor responses. However, the challenge of selectively targeting the diseased tissue without harming the healthy tissue has impeded the development of STING agonists. In this article, we tackle this issue by developing novel STING synergists that target the STING C-terminal domain pocket. Our findings indicate that agonist 12B can boost the cGAMP-STING pathway synergistically. Through reverse optimization of 12B, we synthesized three series of compounds, with compounds 55, 66, and 67 emerging as selective STING synergists that amplify cGAMP-induced pathway activation without inherent agonist properties. Compound 67 emerged as the most potent (EC50 = 20.53 μM), displaying a broad binding affinity across STING-CTD alleles and potent antitumor efficacy in vivo. Notably, it exhibited excellent safety profiles in both in vitro and in vivo models, along with favorable pharmacokinetics. These findings highlight the therapeutic potential of novel STING synergists for cancer immunotherapy.